Amylyx Pharmaceuticals, Inc. (AMLX) Research

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Market snapshot

Symbol
AMLX
Price
$15.67
Day change
+2.75%
Market cap
$1.3B
P/E ratio
-11.54x
52-week range
4.8-18.605
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$27.50

Peer companies

  • Atai Beckley Inc. (ATAI)
  • CureVac N.V. (CVAC)
  • Immatics N.V. (IMTX)
  • Inhibrx Biosciences, Inc. (INBX)
  • Nektar Therapeutics (NKTR)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Precigen, Inc. (PGEN)
  • Relay Therapeutics, Inc. (RLAY)

Recent insider activity

  • Zeiher Bernhardt G — A-Award (24372 shares) on 2026-06-04
  • Firestone Karen — A-Award (24372 shares) on 2026-06-04
  • Quimi Daphne — A-Award (24372 shares) on 2026-06-04
  • MILNE GEORGE M JR — A-Award (24372 shares) on 2026-06-04
  • FONTEYNE PAUL R. — A-Award (24372 shares) on 2026-06-04

Open Amylyx Pharmaceuticals, Inc. (AMLX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.